STEMCELL Technologies StemSpan StemSpan Myeloid Expansion Supplement
- 研究用
StemSpan™ Myeloid Expansion Supplement (100X) は、ヒト臍帯血(CB)または骨髄(BM)から分離されたCD34+細胞の増殖およびミエロイド前駆細胞への分化を選択的に促進し、CD15+顆粒球を大量に産生させる培地サプリメントです。組み換えヒトサイトカイン(SCF、TPO、G-CSF、GM-CSF)を含んでいます。StemSpan™ Myeloid Expansion Supplementを無血清培地に添加すると、通常、CD34+ヒトCB細胞の14日間の液体培養において、CD34+細胞1個あたり数千のCD15+顆粒球を産生できます。
StemSpan™ Myeloid Expansion Supplementは以下のStemSpan™培地と組み合わせた使用を想定しています。
・ StemSpan™ SFEM (ST-09600)
・ StemSpan™ SFEM II (ST-09605)
・ StemSpan™-XF (ST-100-0073)
・ StemSpan™-AOF (ST-100-0130)
製品の特長
StemSpan™ Myeloid Expansion Supplementをもちいて、ヒト顆粒球を増殖および分化できます
- 14日間の液体培養で、1個のヒト 臍帯血(CB)CD34+細胞から数千個のCD15+顆粒球を産生できます
- 100倍濃縮液を解凍して混ぜ、任意の培地に添加するだけで調製が完了します
アプリケーション
- 顆粒球発生の制御に関する研究
- 顆粒球を増やす培養法の開発
データ紹介
StemSpan™ Myeloid Expansion Supplementを添加したStemSpan™ SFEM II 培地をもちいて、ヒトプライマリーセルからミエロイド細胞を効率よく作製できます。
ヒト骨髄細胞の増殖と分化によるCD13+およびCD15+ミエロイド細胞の産生
![Production of CD13+ and CD15+ Myeloid Cells by the Expansion and Lineage-Specific Differentiation of Human BM-Derived Cells Cultured in StemSpan™ SFEM II Containing Myeloid CD34+ Expansion Supplement](https://www.stemcell.com/media/images/data-figures/02693/02693_img01.jpg)
Flow cytometry dot plots for 14-day cultures of human BM-derived CD34+ cells in StemSpan™ SFEM II containing Myeloid Expansion Supplement showing expression of the HSPC marker CD34, and pan-hematopoietic marker CD45 (A) before and (B) after 14 days of culture, and expression of myeloid markers CD13 and CD15 (C) after 14 days of culture. The frequency of CD34+ cells declined from 83% before culture to ~1% after 14 days. In parallel, myeloid CD13+CD15+ cells gradually accumulated from <10% on day 0 to 46% by day 14. The frequency of CD14+ cells after culture was low (typically <10%, see Table 1).
ヒト臍帯血CD34+細胞培養によるミエロイド細胞産生
![Production of Myeloid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ SFEM II Containing Myeloid Expansion Supplement](https://www.stemcell.com/media/images/data-figures/02693/02693_img02.jpg)
Number of total nucleated cells (TNCs) produced per input human CB-derived CD34+ cell from 14 different donors and percentage of cells positive for myeloid markers CD13, CD14 and CD15 produced after 14 days of culture in SFEM II containing Myeloid Expansion Supplement. Best expansion was obtained in SFEM II, but myeloid cell expansion may also be obtained in SFEM and ACF media.
*95% confidence limits (CL), the range within which 95% of the results will typically fall.